Are Weight Loss Medications Safe for Kids? Experts Weigh In

Weight loss treatments like Ozempic and Wegovy have seen a significant increase in popularity among adults. Many are turning to these new options as alternatives to the traditional advice of eating less and exercising more, which often fails to produce desired results. As of this summer, approximately 12% of U.S. adults have used a GLP-1 medication for weight loss or other health conditions. This surge highlights a shift in how people approach weight management, seeking more effective solutions.

Celebrities have played a crucial role in boosting the popularity of GLP-1 treatments. High-profile figures adopting these medications have brought them into the mainstream, making them more recognizable to the general public. The term “Ozempic face” has even entered everyday language, reflecting the widespread attention these treatments are receiving. However, the high demand has also led to the emergence of counterfeit and potentially dangerous versions, raising concerns about safety and authenticity.

As GLP-1 treatments gain recognition among adults, their use among children and adolescents is also on the rise. The Centers for Disease Control and Prevention reports that about one in five children in the U.S. is affected by obesity. In 2023, over 30,000 adolescents aged 12 to 17 were prescribed GLP-1 treatments, according to a study from the University of Michigan. This trend underscores the growing effort to address obesity early in life.

Doctors advocate for early intervention in combating obesity to prevent future health issues. Dr. Chris Straughn, a pediatrician, notes that GLP-1 treatments can be both effective and safe for young patients, although current research only covers a few years of use. Early use of these medications could be a valuable tool in a pediatrician’s arsenal, helping children and teens manage their weight more effectively when combined with healthy habits.

Despite the benefits, there are significant concerns about the long-term effects of GLP-1 treatments in children and adolescents. Dr. Dan Cooper highlights the lack of research on the prolonged use of these medications, particularly during crucial development periods like puberty. There is uncertainty about how these treatments might impact bone development, muscle growth, and brain function over time. This uncertainty makes the decision to prescribe these treatments more complex for healthcare providers.

Parents considering GLP-1 treatments for their children should engage in open discussions with healthcare professionals. Dr. Cooper advises that parents remain vigilant for any signs of depressive symptoms and continue to encourage healthy eating and active lifestyles alongside any medical treatments. It is also important for parents to understand that obesity is influenced by biology, and there should be no shame associated with seeking help. Supportive environments can enhance the effectiveness of any treatment plan.

The growing use of GLP-1 treatments like Ozempic and Wegovy presents both promising opportunities and important challenges in the fight against obesity. While these medications offer a more effective alternative to traditional weight loss advice, their use, especially among children and adolescents, requires careful consideration of the potential long-term impacts. Balancing the benefits of early intervention with the need for more comprehensive research will be crucial in ensuring these treatments are used safely and effectively. As the landscape of weight management continues to evolve, informed decisions by individuals and healthcare providers will play a key role in shaping future outcomes.